公开(公告)号：US11560416B2

公开(公告)日：2023-01-24

申请号：US16606279

申请日：2018-04-20

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun Choi ,  In Hwan Lim ,  Jun Young Park ,  Jin Hyoung Lee ,  Ki Hong Kim ,  Hae Yong Jo ,  Jun Hwan Kim ,  Moo Young Song ,  Jong Gyun Kim

IPC: C12N15/62 ,  C12N15/09 ,  C12N5/00 ,  C07K16/46 ,  C07K19/00 ,  C07K14/605 ,  C07K14/50 ,  C12P21/02 ,  C12N15/00

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US11179440B2

公开(公告)日：2021-11-23

申请号：US16348249

申请日：2017-11-10

Applicant: YUHAN CORPORATION

Inventor： Han Na Hong ,  Jun Hwan Kim ,  Hyun Ho Choi ,  Dohoon Kim ,  Taewang Kim ,  Se Woong Oh ,  Moo Young Song ,  Jong Gyun Kim

IPC: A61K38/18 ,  A61P1/16 ,  A61K38/17 ,  A61K38/26

Abstract: A fusion protein containing a biologically active protein and an FGF21 mutant protein, a pharmaceutical composition containing the fusion protein, and their uses are disclosed. The fusion protein and the pharmaceutical composition are effective in treating a liver disease including hepatitis, hepatic fibrosis, and hepatic cirrhosis. The fusion protein has effects of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.

公开(公告)号：US11981659B2

公开(公告)日：2024-05-14

申请号：US17697655

申请日：2022-03-17

Applicant: Yuhan Corporation

Inventor： Sang Ho Oh ,  Jong Gyun Kim ,  Se-Woong Oh ,  Tae Dong Han ,  Soo Yong Chung ,  Seong Ran Lee ,  Kyeong Bae Kim ,  Young Sung Lee ,  Woo Seob Shin ,  Hyun Ju ,  Jeong Ki Kang ,  Su Min Park ,  Dong Kyun Kim

IPC: C07D403/04 ,  C07C303/22 ,  C07C309/04

CPC classification number: C07D403/04 ,  C07C303/22 ,  C07C309/04 ,  C07B2200/13

Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.

公开(公告)号：US11453656B2

公开(公告)日：2022-09-27

申请号：US16605944

申请日：2018-04-18

Applicant: Yuhan Corporation

Inventor： Sang Ho Oh ,  Jong Gyun Kim ,  Se-Woong Oh ,  Tae Dong Han ,  Soo Yong Chung ,  Seong Ran Lee ,  Kyeong Bae Kim ,  Young Sung Lee ,  Woo Seob Shin ,  Hyun Ju ,  Jeong Ki Kang ,  Su Min Park ,  Dong Kyun Kim

IPC: C07C309/04 ,  C07C303/22 ,  C07C403/04 ,  C07D403/04

Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.

公开(公告)号：US11136364B2

公开(公告)日：2021-10-05

申请号：US15768865

申请日：2016-10-28

Applicant: YUHAN CORPORATION

Inventor： Jun Hwan Kim ,  Seyoung Lim ,  Minji Seo ,  Hyun Ho Choi ,  Dohoon Kim ,  Mi Kyeong Ju ,  Ju-Young Park ,  Seul Gi Kim ,  Sangmyoun Lim ,  Jong Gyun Kim ,  Su Youn Nam

IPC: A61K38/18 ,  C07K14/50 ,  C07K14/575 ,  C07K14/605

Abstract: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.

公开(公告)号：US20190153055A1

公开(公告)日：2019-05-23

申请号：US16097572

申请日：2017-04-19

Applicant: YUHAN CORPORATION

Inventor： Su Youn Nam ,  Jong Gyun Kim ,  Byung Hyun Choi ,  June Hyung Lee ,  Ju Young Park ,  Jun Kyung Lee ,  Na Rae Lee ,  Ki Hong Kim ,  Seul Gi Kim ,  Se Woong Oh ,  Seung Yub Shin ,  Ho Woong Kang ,  Su Jin Ahn ,  Soo Yong Chung

IPC: C07K14/52 ,  A61P35/00

Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.

公开(公告)号：US11142557B2

公开(公告)日：2021-10-12

申请号：US15768616

申请日：2016-10-28

Applicant: YUHAN CORPORATION

Inventor： Jun Hwan Kim ,  Seyoung Lim ,  Minji Seo ,  Hyun Ho Choi ,  Dohoon Kim ,  Mi Kyeong Ju ,  Ju-Young Park ,  Byung Hyun Choi ,  Jun Kyung Lee ,  Jong Gyun Kim ,  Su Youn Nam

IPC: A61K38/18 ,  C07K14/50 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

公开(公告)号：US11046742B2

公开(公告)日：2021-06-29

申请号：US16097572

申请日：2017-04-19

Applicant: YUHAN CORPORATION

Inventor： Su Youn Nam ,  Jong Gyun Kim ,  Byung Hyun Choi ,  June Hyung Lee ,  Ju Young Park ,  Jun Kyung Lee ,  Na Rae Lee ,  Ki Hong Kim ,  Seul Gi Kim ,  Se Woong Oh ,  Seung Yub Shin ,  Ho Woong Kang ,  Su Jin Ahn ,  Soo Yong Chung

IPC: C07K14/52 ,  C07K19/00 ,  C12N15/09 ,  C12N15/11 ,  C12N15/63 ,  A61K38/19 ,  A61K47/68 ,  A61P35/00 ,  A61K38/00 ,  A61K47/50

Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.